Related Experiment Video

Updated: May 13, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

IL-8 -251T/A and IL-12B 1188A/C polymorphisms are associated with gout in a Chinese male population

S Liu1, C Yin, N Chu

  • 1Shandong Provincial Key Laboratory of Metabolic Disease, Qingdao University, Qingdao, PR China.

Scandinavian Journal of Rheumatology
|February 28, 2013
PubMed
Abstract

Insights

Genetic variations in interleukin-8 (IL-8) and interleukin-12 (IL-12) are linked to gout susceptibility in Chinese men. These findings highlight specific gene polymorphisms as potential risk factors for developing gout.

Area of Science:

  • Immunogenetics
  • Rheumatology
  • Molecular Biology

Background:

  • Gout is an inflammatory joint disease caused by monosodium urate (MSU) crystals.
  • MSU crystals trigger inflammation via NALP3 inflammasome activation, leading to interleukin-1 beta (IL-1β) generation.
  • Interleukin-8 (IL-8) and IL-12 are key chemokines in initiating and amplifying inflammatory responses, particularly neutrophil influx into joints.

Purpose of the Study:

  • To investigate the association between IL-8 -251T/A and IL-12B 1188A/C gene polymorphisms and gout susceptibility.
  • To determine if these polymorphisms are relevant host factors for gout development in a Chinese Han male population.

Main Methods:

  • Genotyping of 387 gout patients and 576 controls using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP).
  • Association analysis conducted using the chi-squared (χ2) test.
  • Genotype-phenotype analysis performed to correlate genetic variations with gout status.

Main Results:

  • The T allele of IL-8 -251 was significantly associated with an increased risk of gout (p = 0.031, OR = 1.229).
  • Significant associations were found between IL-12B 1188 gene polymorphisms (AA and AC genotypes, A allele) and gout cases compared to controls (p < 0.001 for both genotype and allele frequencies).
  • The IL-12B 1188 A allele showed a higher frequency in gout patients (OR = 1.404).

Conclusions:

  • The IL-8 -251T/A and IL-12B 1188A/C polymorphisms are suggested as potential host susceptibility factors for gout.
  • These genetic variations may play a role in the development of gout in the studied Chinese Han male population.

More Related Videos

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification10:21

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...